SCHEMBL17391748

SCHEMBL17391748

CCc1cc(-c2cc(OCOCC[Si](C)(C)C)c3ncn(COCC[Si](C)(C)C)c(=O)c3c2)sc1C(=O)O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.33
▸ RAB9A P51151 4/20 0.33
▸ SMN1; SMN2 Q16637 4/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ NFKB1 P19838 2/20 0.33
▸ NFKB2 Q00653 2/20 0.33
▸ RELA Q04206 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ SENP8 Q96LD8 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33
▸ SENP6 Q9GZR1 1/20 0.33
▸ F2RL3 Q96RI0 1/20 0.32
▸ HPGD P15428 2/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ EGFR P00533 1/20 0.31
▸ IGF1R P08069 1/20 0.31
▸ SRC P12931 1/20 0.31
▸ FLT4 P35916 1/20 0.31
▸ KDR P35968 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15845841 0.82 NPC1 (0.38) NPC1KDM4EEGFRIGF1RSRC
SCHEMBL15846300 0.82 CD38 (0.34) EGFRIGF1RSRCFLT4KDR
SCHEMBL15845679 0.81 PTPN1 (0.32) SMN1; SMN2ALDH1A1KDM4EF2RL3HPGD
SCHEMBL15859688 0.79 EGFR (0.39) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
SCHEMBL17391755 0.79 PTPN11 (0.37) NPC1EGFRIGF1RSRCFLT4
SCHEMBL15846413 0.79 EIF4EBP1 (0.42) —
SCHEMBL15846199 0.77 EGFR (0.36) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
SCHEMBL17391750 0.77 F2RL3 (0.34) F2RL3EGFRIGF1RSRCFLT4
SCHEMBL15846275 0.77 F2RL3 (0.34) F2RL3EGFRIGF1RSRCFLT4
SCHEMBL15845858 0.77 EGFR (0.35) NPC1SMN1; SMN2ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 — — US disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 NPC1 2621/4885RAB9A 341/4885SMN1; SMN2 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback